Skip to main content
Elsevier

Advances in DNA and mRNA-Based strategies for Cancer Immunotherapy: Part B

  • 1st Edition, Volume 166 - July 30, 2025
  • Latest edition
  • Editors: Kenneth Murphy, Arun Kumar Singh, Frederick Alt, Neeraj Mishra, Sumel Ashique, Pranav Kumar Prabhakar
  • Language: English

Advances in Immunology, Volume 166, the latest release in a long-established and highly respected publication, presents current developments and comprehensive reviews in immuno… Read more

Description

Advances in Immunology, Volume 166, the latest release in a long-established and highly respected publication, presents current developments and comprehensive reviews in immunology.

Key features

  • Presents current developments and comprehensive reviews in immunology
  • Provides the latest in a longstanding and respected serial on the subject matter
  • Focuses on recent advances in the field of immunology

Readership

Immunologists and infectious disease specialists, cell biologists and hematologists

Table of contents

1. Harnessing the immune system: Insights into cancer vaccines

Sushree Subhadra Acharya, Subhasmita Bhal, Biswajit Das, and

Chanakya Nath Kundu

2. Lipid nanoparticle mediated mRNA delivery in cancer immunotherapy

Gyati Shilakari Asthana, Saptarshee Bhattacharjee, Jitendra Kumar, Soyal Sayyed, Amulya Jindal, Pankaj Kumar, Abhijeet Chinchane, Atreyee Bhattacharyya, Roshani Jaiswal,

Sagar Kulkarni, Shubham Gajdhane, Jitender Madan, and Abhay Asthana

3. Nanoparticles for mRNA-based cancer immunotherapy

Rakesh Pahwa, Gulshan Sharma, Rohil Panwar, and Neeraj Mishra

4. B-cell editing: An emerging alternative of precision oncotherapy

Pritha Roy Choudhury, Mohona Chakravarti, Saptak Banerjee,

Rathindranath Baral, and Anamika Bose

5. Personalized precision: Revolutionizing cancer treatment with mRNA-based vaccines in melanoma therapy

Krishnendu Adhikary, Abhik Paul, Ayush Madan, Anas Islam, Sumel Ashique,
and Mohhammad Ramzan

6. Revolutionizing cancer treatment: Exploring novel immunotherapeutics, checkpoints, bispecifics, and vaccines in development

Anas Islam, Vijay Singh, Pooja S. Murkute, Sumel Ashique,

Shriyansh Srivastava, Mohammad Yousuf Ansari, and Sabina Yasmin

7. Recent progress, challenges (stability and in vivo distribution), and opportunities of DNA & mRNA vaccine in cancer immunotherapy

Monika Kaushik, Prathap Madeswaraguptha, Murugesan Vanangamudi, Vijayaraj Surendran, Sumel Ashique, Anas Islam, Naheed Mojgani, and Afzal Hussain

Product details

  • Edition: 1
  • Latest edition
  • Volume: 166
  • Published: August 15, 2025
  • Language: English

About the editors

KM

Kenneth Murphy

Kenneth M. Murphy works in Washington University School of Medecine, USA.
Affiliations and expertise
Washington University School of Medecine, USA

AS

Arun Kumar Singh

Arun Kumar Singh is Assistant Professor in the Department of Pharmacy at Vivekanand Global University, India. His teaching and research activities span pharmaceutical sciences and a range of interdisciplinary fields, including nanoformulation, cancer biology, artificial intelligence, machine learning, blockchain technology, the Internet of Things, big data analytics, and neuroscience. He has contributed to scholarly publishing through authorship and editorial work and has participated in research and academic initiatives that integrate emerging technologies with healthcare and pharmaceutical applications. His interests focus on advancing innovative approaches to drug delivery, biomedical research, and technology-enabled solutions for healthcare challenges.

Affiliations and expertise
Assistant Professor, University School of Pharmaceutical Sciences, Rayat Bahra University V.P.O. Sahauran, Tehsil Kharar, Distt. Mohali, Punjab, India

FA

Frederick Alt

Frederick W. Alt is a Howard Hughes Medical Institute (HHMI) Investigator and Director of the Program in Cellular and Molecular Medicine (PCMM) at Boston Children's Hospital (BCH). He is the Charles A. Janeway Professor of Pediatrics and Professor of Genetics at Harvard Medical School. He works on elucidating mechanisms that generate antigen receptor diversity and, more generally, on mechanisms that generate and suppress genomic instability in mammalian cells, with a focus on the immune and nervous systems. Recently, his group has developed senstive genome-wide approaches to identify mechanisms of DNA breaks and rearrangements in normal and cancer cells. He has been elected to the U.S. National Academy of Sciences, the U.S. National Academy of Medicine, and the European Molecular Biology Organization. His awards include the Albert Szent-Gyorgyi Prize for Progress in Cancer Research, the Novartis Prize for Basic Immunology, the Lewis S. Rosensteil Prize for Distinugished work in Biomedical Sciences, the Paul Berg and Arthur Kornberg Lifetime Achievement Award in Biomedical Sciences, and the William Silan Lifetime Achievement Award in Mentoring from Harvard Medical School.
Affiliations and expertise
Professor of Pediatrics and Professor of Genetics, Harvard Medical School, Boston, MA, USA

NM

Neeraj Mishra

Neeraj Mishra is Professor and Head of the Department of Pharmaceutics at the Amity Institute of Pharmacy, Amity University Madhya Pradesh, Gwalior, India. His academic work focuses on novel drug delivery systems, including localized, targeted, and controlled delivery approaches using nanocarrier and microparticle-based technologies. His research interests encompass therapies for cancer and neurodegenerative disorders, and he has extensive experience in teaching, research supervision, and scholarly publishing. He has also contributed to innovation in pharmaceutical sciences through intellectual property development and collaborative academic activities. Through his research and educational initiatives, he supports the advancement of drug delivery strategies and pharmaceutical research.

Affiliations and expertise
Professor & Head, Department of Pharmaceutics, Amity Institute of Pharmacy, Amity University, Gwalior, Madhya Pradesh, India

SA

Sumel Ashique

Dr. Sumel Ashique has been working as an assistant professor at the Department of Pharmaceutical Technology, School of Health and Medical Sciences, Adamas University, West Bengal, India. He has 5 years of teaching experience. He has achieved 100+ publications in international and national accredited reputed journals. He has expertise in drug delivery, nanotechnology, and targeted treatment strategies. Recently, he was honored to be in the World’s Top 2% Scientists by prestigious Stanford University, CA, United States, and Elsevier in 2025.

Affiliations and expertise
Department of Pharmaceutical Technology, School of Health and Medical Sciences, Adamas University, Kolkata, West Bengal, India

PP

Pranav Kumar Prabhakar

Pranav Kumar Prabhakar is Professor and Head of the Department of Biotechnology, School of Engineering and Technology, Nagaland University, Kohima, India. His research focuses on understanding molecular mechanisms involved in metabolic disorders, particularly diabetes, and on developing strategies for oral insulin delivery using natural products and biotechnology-based approaches. He is actively involved in research, academic mentoring, peer review, and editorial activities within the biomedical and biotechnology fields. His professional interests include translational research, signaling pathways associated with metabolic diseases, and the application of biotechnology to improve therapeutic outcomes. He contributes to scientific and academic initiatives that support advancements in biotechnology and healthcare research.

Affiliations and expertise
Professor & Head, Department of Biotechnology, School of Engineering and Technology, Nagaland University, Meriema, Kohima, Nagaland, India

View book on ScienceDirect

Read Advances in DNA and mRNA-Based strategies for Cancer Immunotherapy: Part B on ScienceDirect